Best Cancer treatment in India By Cancer Fax

Best Cancer treatment in India By Cancer Fax
Share via:

Companies like Immunoact, Cellogen and Immuneel are making CAR T cell therapy in India. Indian Govt has paid a lot of attention to CAR T-cell treatment in India, which is a new kind of immunotherapy. In this new treatment, the patient’s own immune cells are reprogrammed to find and kill cancer cells. In the past few years, Indian hospitals and study centres have come a long way towards using CAR T-cell therapy. CAR T-cell therapy could change the way cancer is treated, so it gives patients who don’t have many other choices new hope. There are plans to create and make CAR T-cell therapy in India, which would make them easier to get and cheaper. 


What is the scope of CAR-T Cell Therapy in India?

Introduction: CAR T- cell therapy is a new type of treatment that is changing the way cancer is treated all over the world. In the past few years, India has made a lot of progress in adopting this cutting-edge treatment, giving patients with different kinds of cancer new reasons to hope. CAR-T cell therapy is likely to have a huge effect on Indian health care because it could change the way cancer is treated.


What is the cost of CAR T-Cell therapy in India?

The cost of CAR-T cell therapy in India is around $ 57,000 USD. This can change based on a number of things. These hospital’s have collaborated with Malaysian company to bring CAR T-Cell treatment in India. It’s important to remember, though, that these numbers can change and may be different in different hospitals and care centres. The cost may also change depending on the type of CAR-T cell therapy that is needed and the state of the patient. 
However, very soon home grown CAR T-Cell therapies like Immunoact, Immuneel and Cellogen will be alunching their own CAR T-Cell therapies and their cost is going to be in the range of $30-40,000 USD. This will make India most affordable destination for CAR T-Cell therapy treatment.

How effective is CAR-T Cell therapy?

CAR T-cell therapy has been very effective in treating some types of blood cancer, like acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma. In clinical trials, the response rates have been very good, and a lot of patients have gone into full remission. In some cases, people who had tried every other medicine had long-lasting remissions or even possible cures.

One of the best things about CAR T-cell treatment is that it targets the right cells. The CAR receptors that have been added to the T cells can find specific marks on cancer cells. This makes it possible to give targeted treatment. This targeted method hurts healthy cells as little as possible and lowers the risk of side effects that come with traditional treatments like chemotherapy.

What are the advantages of CAR-T Cell Therapy?

The main benefit is that CAR T-cell therapy only requires a single infusion and often only requires two weeks of inpatient care. Patients with non-Hodgkin lymphoma and pediatric leukemia who have just been diagnosed, on the other hand, typically need chemotherapy for at least six months or more.

The advantages of CAR T-cell therapy, which is actually a living medication, can persist for many years. If and when a relapse occurs, the cells will still be able to identify and target cancer cells because they can survive in the body for an extended period of time. 

Although the information is still developing, 42% of adult lymphoma patients who underwent CD19 CAR T-cell treatment were still in remission after 15 months. And after six months, two-thirds of patients with pediatric acute lymphoblastic leukemia were still in remission. Unfortunately, these patients had exceedingly aggressive tumors that weren’t successfully treated using traditional standards of care.

What type of patients would be good recipients of the CAR-T Cell Therapy?

Patients between the age of 3 Years to 70 Years have been tried with CAR T-Cell therapy for different type of blood cancers and has been found to be very effective. Many centers have claimed success rates of more than 80%. The optimum candidate for CAR T-cell therapy at this time is a juvenile with acute lymphoblastic leukemia or an adult with severe B-cell lymphoma who has already had two lines of ineffective therapy. 

Before the end of 2017, there was no accepted standard of care for patients who had already gone through two lines of therapy without experiencing remission. The only FDA-approved treatment that has so far proven to be significantly beneficial for these patients is CAR T-cell therapy.



Contact Us :









Leave a Comment


No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *